Last edition
News about "Risvutatug Rezetecan"
Ris-Rez Cuts Risk of Death by 54 Percent vs Topotecan in Relapsed SCLC in China
Ris-Rez reduced the risk of death by 54 percent versus topotecan in relapsed SCLC in China, extending median overall survival to 18.5 months versus 10.3 months with comparator.
Risvutatug Rezetecan | 15/09/2026 | By News Bureau
Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China
Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.
Risvutatug Rezetecan | 31/07/2026 | By News Bureau
GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer
Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.
Risvutatug Rezetecan | 24/03/2026 | By News Bureau | 218
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy